CN1450087A - Recombinant Toxoplasma fusion protein antigen and preparation process and use thereof - Google Patents
Recombinant Toxoplasma fusion protein antigen and preparation process and use thereof Download PDFInfo
- Publication number
- CN1450087A CN1450087A CN 03113429 CN03113429A CN1450087A CN 1450087 A CN1450087 A CN 1450087A CN 03113429 CN03113429 CN 03113429 CN 03113429 A CN03113429 A CN 03113429A CN 1450087 A CN1450087 A CN 1450087A
- Authority
- CN
- China
- Prior art keywords
- thr
- ser
- gly
- ala
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The present invention relates to recombinant toxoplasma fusion protein, its preparation method and application. It utilizes gene engineering technology to prepare a new-type recombinant toxoplasma protein, i.e. the fusion protein formed from 110 amino acids from 43-th amino acid to 152-th amino acid of toxoplasma GRA6 protein N end and 258 amino acids from 56-th amino acid to 313-th amino acid of P30 protein which are series-connected. The above-mentioned 110 amino acids of GRA6 protein N end is positioned at fusion protein N end, and the 258 amino acids of P30 protein is positioned at C end of the fusion protein, and between them 2 amino acids of Gly and Ser are connected, and one methionine (Met) is added at N end of fusion protein, its total length has 371 amino acids.
Description
Technical field
The present invention utilizes genetic engineering technique, preparation recombinant toxoplasma fusion rotein.Toxoplasma GRA6 albumen and P30 albumen that two fragments of fusion rotein come from respectively, two fragments are utilized genetic engineering technique to connect and are expressed, form new fusion rotein, the new fusion protein of generation can be used as antigen, is used for toxoplasma antibody or detection of antigens etc.The present invention relates to genetic engineering technique and diagnostic reagent field.
Background technology
Toxoplasmosis claims toxoplasmosis again, is that a kind of people beast suffers from parasitosis altogether, and this disease belongs to the category of parasitosis, is worldwide distribution.Its pathogenic agent of toxoplasmosis is a kind of coccidia, and whole life history of the growth course of toxoplasma gondii needs two hosts, and feline is the final host as domestic cat, but it is not strict to middle host's the selection utmost point, and no matter mammals or birds can be as the intermediate hosts.If the pet (as cat, dog, bird etc.) in the family has infected toxoplasma or you and has eaten to have infected meat product, milk preparation, the eggs that toxoplasma but boils not yet donely and imported to infect toxoplasmatic blood plasma is arranged, all will have an opportunity toxoplasmosis.According to another report, insects such as mosquito, fly, cockroach also can be carried to toxoplasma on people's the food or in the drinking-water, thereby can cause people's infection.
Human infection is generally inapparent infection, and majority may be asymptomatic carrier, only a few peoples' morbidity.Polypide can be invaded multiple internal organs and tissue, this disease complicated clinical manifestation, and the lighter is inapparent infection, weight person can show as the grievous injury of many organs, as the pathology of each system such as toxoplasma gondii encephalopathic, illness in eye, ephrosis, hepatopathy, tuberculosis and toxoplasma myocarditis.And can cause fetal anomaly by mother and baby's vertical transmission, nervous system disorder, choroidoretinitis etc.It should be noted that toxoplasma has very significant effects to gestation.Pregnant woman by toxoplasma infects no matter it has or not clinical symptom, often can pass to fetus with toxoplasma gondii by placenta, thereby directly influence the growth of fetus, makes the serious teratogenesis of fetus, even dead, also can miscarry, stillbirth, premature labor or increase pregnancy complication.Infection takes place more early, and fetus is impaired serious more.Infection occurs in timester, how can cause miscarriage, stillbirth or give birth to no viability with grow defective baby; The second trimester of pregnancy infect, stillborn foetus, premature labor and serious brain, eye illness how can occur and suffer from; In third trimester of pregnancy, ripe gradually because of fetus, parent is as being infected at this moment, and fetus can grow normally, also can occur symptom just occurring after premature labor or the birth, shows as the damage in various degree of each system.It is reported that the fetus of accidental pregnancy period toxoplasma gondii infection just shows toxoplasmosis behind several years after the birth even adult.As seen toxoplasma gondii is very harmful to the mankind, especially the pregnant woman.Therefore, the key object of control toxoplasmosis should be the child-bearing period women.In addition, recent studies show that, arch insect infection and infertile certain relation arranged, and sexual behaviour may be a kind of approach (Chinese Amphixenosis's magazine, 2000 that toxoplasma gondii is propagated between the man and wife; 16 (3)).The method for quick of setting up arch insect infection detects the child-bearing period women, to prenatal and postnatal care significance again.
The toxoplasmosis diagnostic method mainly comprises at present: (1) biopsy and animal inoculation pvaccination.Low, the consuming time length of this method success ratio.(2) PCR detects toxoplasma cdna.This method has higher susceptibility, but false positive is arranged.(3) the ELISA method detects special IgG and the IgM of toxoplasma gondii.This is to use more method, the positive explanation of the IgM recent infection that intraserous toxoplasma gondii is special toxoplasma gondii, if pregnant woman's best termination of pregnancy then.
Multiple toxoplasma protein can stimulate body to produce corresponding antibody.The special antibody test reagent of development toxoplasma gondii should be selected the proteantigen that antigenicity is strong, specificity is good for use.Mostly the toxoplasma protein antigen that China uses is the toxoplasma gondii extract of cultivation, contains a plurality of protein products, and antigen-specific is not strong, easily produces false positive.External studies confirm that the GRA6 albumen of toxoplasma gondii [Lecordier L, Fourmaux MP, Mercier C.et al.Clin DiagnLab Immunol.2000 Jul; 7 (4): 607-11] and P30 albumen [Nam HW, Im KS, Baek EJ, et al.Korean J Parasitol.1996; 34 (2): 135-41] have stronger antigenicity, its corresponding antibody recall rate is higher in arch insect infection person's serum.According to GRA6 albumen and the proteic aminoacid sequence of P30, by Computer Analysis, we filter out and select antigenic determinant stronger in it for use, include the gene fragment of antigenic determinant with increased respectively GRA6 albumen and P30 albumen of PCR method, two gene fragment series connection are cloned into same plasmid expression vector, successfully constructed the engineering bacteria that efficiently expresses both fusion roteins, set up the purification process of expressing protein, purifying has obtained highly purified fusion rotein, and as the Detection of antigen toxoplasma antibody.
Summary of the invention
The present invention utilizes genetic engineering technique to prepare a kind of novel recombinant toxoplasma protein, be the fusion rotein of toxoplasma gondii GRA6 albumen n end from 152 amino acid whose 110 amino acid of the 43rd amino acid to the and 313 amino acid whose 258 amino acid series connection formation of proteic the 56th amino acid to the of P30,110 amino acid of GRA6 albumen n end are held at fusion rotein N, proteic 258 amino acid of P30 are at the C of fusion rotein end, be connected by 2 amino acid of glycine (Gly) and Serine (Ser) between the two, the N end of fusion rotein has increased by 1 egg base acid (Met), 371 amino acid of total length.This albumen is used to detect toxoplasma antibody or antigen and is used for the immune resisting toxoplasmosis monoclonal antibody and how anti-for preparing.Recombinant toxoplasma fusion rotein and preparation method thereof, application take following steps to implement: toxoplasma gondii GRA6 albumen and the screening of P30 proteantigen epi-position and the clone of gene fragment: the 1) screening of epitope
Utilize softwares such as ANTHEWIN, by the proteic whole aminoacid sequence (GeneBank of Computer Analysis toxoplasma gondii GRA6, closing number: L33814) with the proteic whole aminoacid sequence (GeneBank of P30, closing number: S73634), the strong antigen epi-position that filters out in the toxoplasma gondii GRA6 albumen is positioned at 152 amino acid of the 43rd amino acid to the; Strong antigen epi-position in the P30 albumen is positioned at 313 amino acid of the 56th amino acid to the.Their aminoacid sequence and dna sequence dna are as follows:
Epitope amino acid sequence in the screening Infection of Toxoplasma Gondii GRA6 albumen (43aa～152aa): Ala Ala Asp Ser Gly Gly Val Lys Gln Thr Pro Ser Glu Thr Gly Ser Ser Gly GlyGln Gln Glu Ala Val Gly Thr Thr Glu Asp Tyr Val Asn Ser Ser Ala Met Gly GlyGly Gln Gly Asp Ser Leu Ala Glu Asp Asp Thr Thr Ser Glu Ala Ala Glu Gly AspVal Asp Pro Phe Pro Val Leu Ala Asn Glu Gly Lys Ser Glu Ala Arg Gly Pro SerLeu Glu Glu Arg Ile Glu Glu Gln Gly Thr Arg Arg Arg Tyr Ser Ser Val Gln GluPro Gln Ala Lys Val Pro Cys Lys Arg Thr Gln Lys Arg His Arg
The dna sequence dna (547～876bp): GCA GCA GAC AGC GGT GGT GTT AAG CAG ACC CCT TCG GAA ACC GGT TCG AGC GGT GGACAG CAA GAA GCA GTG GGG ACC ACT GAA GAC TAT GTC AAC TCT TCG GCG ATG GGC GGTGGC CAA GGC GAC TCG TTA GCT GAA GAT GAT ACA ACC TCC GAA GCG GCG GAG GGC GACGTT GAC CCT TTT CCC GTG CTG GCG AAT GAG GGG AAG TCG GAG GCG CGT GGC CCG TCGCTC GAG GAA AGA ATC GAA GAA CAG GGC ACA AGA CGA CGT TAC TCC TCT GTT CAA GAACCA CAA GCG AAG GTG CCT AGC AAA CGA ACA CAG AAA CGC CAC AGA of the Infection of Toxoplasma Gondii GRA6 Protein Epitopes of screening
P30 ( 56aa～313aa ) ：Gln Val Val Thr Cys Pro His Lys Lys Ser Thr Ala Ala Val Ile Leu Thr Pro ThrGlu Asn His Phe Thr Leu Lys Cys Pro Lys Thr Ala Leu Thr Glu Pro Pro Thr LeuAla Tyr Ser Pro Asn Arg Gln Ile Cys Pro Ala Gly Thr Thr Ser Ser Cys Thr SerLys Ala Val Thr Leu Ser Ser Leu Ile Pro Glu Ala Glu Asp Ser Trp Trp Thr GlyAsp Ser Ala Ser Leu Asp Thr Ala Gly Ile Lys Leu Thr Val Pro Ile Glu Lys PhePro Val Thr Thr Gln Thr Phe Val Val Gly Cys Ile Lys Gly Asp Asp Ala Gln SerCys Met Val Thr Glu Thr Val Gln Ala Arg Ala Ser Ser Val Val Asn Asn Val AlaArg Cys Ser Tyr Gly Ala Asp Ser Thr Leu Gly Pro Val Lys Val Ser Ala Glu GluPro Thr Thr Met Thr Leu Val Cys Gly Lys Asp Gly Val Lys Val Pro Gln Asp AsnAsn Gln Tyr Cys Ser Gly Thr Thr Leu Thr Gly Cys Asn Glu Lys Ser Phe Lys AspIle Leu Pro Lys Leu Thr Glu Asn Pro Trp Gln Gly Asn Ala Ser Ser Asp Lys GlyAla Thr Leu Thr Ile Lys Lys Glu Ala Phe Pro Ala Glu Ser Lys Ser Val Ile IleGly Cys Thr Gly Gly Ser Pro Glu Lys His His Cys Thr Val Lys Leu Glu Phe AlaGly Ala Ala Gly Ser Ala Lys Ser Ala Ala Gly
P30DNA ( 166bp～939bp ) ：CAA GTT GTC ACC TGC CCA CAT AAA AAA TCG ACA GCC GCG GTC ATT CTC ACA CCG ACGGAG AAC CAC TTC ACT CTC AAG TGC CCT AAA ACA GCG CTC ACA GAG CCT CCC ACT CTTGCG TAC TCA CCC AAC AGG CAA ATC TGC CCA GCG GGT ACT ACA AGT AGC TGT ACA TCAAAG GCT GTA ACA TTG AGC TCC TTG ATT CCT GAA GCA GAA GAT AGC TGG TGG ACG GGGGAT TCT GCT AGT CTG GAC ACG GCA GGC ATC AAA CTC ACA GTT CCA ATC GAG AAG TTCCCC GTG ACA ACG CAG ACG TTT GTG GTC GGT TGC ATC AAG GGA GAC GAC GCA CAG AGCTGT ATG GTC ACG GAG ACA GTA CAA GCC AGA GCC TCA TCG GTC GTC AAT AAT GTC GCAAGG TGC TCC TAC GGT GCA GAC AGC ACT CTT GGT CCT GTC AAG GTG TCT GCG GAA GAACCC ACT ACA ATG ACC CTC GTG TGC GGG AAA GAT GGA GTC AAA GTT CCT CAA GAC AACAAT CAG TAC TGT TCC GGG ACG ACG CTG ACT GGT TGC AAC GAG AAA TCG TTC AAA GATATT TTG CCA AAA TTA ACT GAG AAC CCG TGG CAG GGT AAC GCT TCG AGT GAT AAG GGTGCC ACG CTA ACG ATC AAG AAG GAA GCA TTT CCA GCC GAG TCA AAA AGC GTC ATT ATTGGA TGC ACA GGG GGA TCG CCT GAG AAG CAT CAC TGT ACC GTG AAA CTG GAG TTT GCCGGG GCT GCA GGG TCA GCA AAA TCG GCT GCG GGA2 ) GRA6P30
Select design PCR primer in the both sides of the dna sequence dna of shape worm GRA6 proteantigen epi-position.The upstream primer of design is GRA6P1 (547-565bp): 5 '-GCGAGTCA
CCATGGCAGCAGACAGCGGTGGTG-3 '; Downstream primer is GRA6P2 (856-876bp): 5 '-CGC
GGATCCTCTGTGGCGTTTCTGTGTTCG-3 '.On upstream primer, increased NcoI restriction enzyme site (following setting-out part), and increased by 8 protection bases, be beneficial to the cutting of NcoI enzyme at 5 ' weak point.On downstream primer, increase BamHI restriction enzyme site (following setting-out part).
Select design PCR primer in the both sides of the dna sequence dna of shape worm P30 proteantigen epi-position.The upstream primer of design is P30P3 (166-184bp): 5 '-CTG
GGATCCCAAGTTGTCACCTGCCCA-3 '; Downstream primer is P30P4 (922-939bp): 5 '-GTC
GAATTCTTATCCCGCAGCCGATTTTGC-3 '.On upstream primer, increased BamHI restriction enzyme site (following setting-out part), and increased by 3 protection bases, be beneficial to the cutting of BamHI enzyme at 5 ' weak point.On downstream primer, increase EcoRI restriction enzyme site (following setting-out part) and give terminator codon (italic).
Get the toxoplasma gondii 100 μ l (Agricultural University Of Nanjing provides) that mouse is cultivated, centrifugal, the collecting precipitation polypide suspends with 200 μ l TE solution (50mmol/L Tris-HCl pH8.0,0.5mmol/L EDTA), add 100 μ l Proteinase Ks (10mg/ml), put 56 ℃ of water-baths 4 hours.With phenol/chloroform method purifying bow-shaped worm dna, the bow-shaped worm dna that obtains is dissolved in the 20 μ l deionized waters, put-20 ℃ frozen standby.
Bow-shaped worm dna with above-mentioned purification is a template, with the gene fragment of primer GRA6P1 and GRA6P2 pcr amplification toxoplasma gondii GRA6 proteantigen epi-position, with the gene fragment of primer P30P3 and P30P4 pcr amplification toxoplasma gondii P30 proteantigen epi-position.Amplification condition is: 94 ℃ 30 seconds, 65 ℃ 30 seconds, 72C 60 seconds, 35 circulations; Last 72 ℃ were extended 7 minutes.Electrophoresis reclaims, the gene fragment of purifying amplification, is dissolved in the deionized water, put-20 ℃ frozen standby.Express toxoplasma gondii GRA6 and P30 fusion rotein construction of recombinant plasmid:
Extract plasmid pET28a (+) (U.S. Novagen company product),, reclaim the big fragment of plasmid that enzyme is cut behind the electrophoresis, be dissolved in the deionized water with Nco I and EcoR I double digestion.With Nco I and BamH I double digestion toxoplasma gondii GRA6 gene fragment, its 5 ' formation Nco I sticky end, 3 ' end is dissolved in the deionized water after forming the recovery of BamH I sticky end electrophoresis.With the P30 protein gene fragment of EcoR I and BamH I double digestion purifying, electrophoresis is dissolved in the deionized water after reclaiming.
Above-mentioned three kinds of enzymes of volumetric molar concentration such as get and cut the back dna fragmentation, in same centrifuge tube, connect with the T4 dna ligase, toxoplasma gondii GRA6 gene fragment is connected with P30 protein gene fragment be inserted between carrier pET28a (+) interior the Nco I and EcoR I site, both translate the framework unanimity, express a fusion rotein.The screening of recombinant plasmid and evaluation:
With recombinant plasmid transformed e. coli bl21 (DE3), coating contains kantlex (60 μ g/ml) LB flat board, 37 ℃ of of of and spends of puts the night.Next day, picking transformed a bacterium colony and a contrast bacterium (plasmid pET28a transformed bacteria) at random, extracted plasmid respectively.It is right at first to form primer with primer GRA6P1 and primer P30P4, is that template is carried out the PCR evaluation with the plasmid that extracts, and contains the plasmid of toxoplasma gondii GRA6 gene fragment and P30 protein gene fragment tandem gene, should amplify a 1132bp gene fragment. extract the plasmid that contains Infection of Toxoplasma Gondii GRA6 GFP fragment and P30 GFP fragment tandem gene and carry out dna sequence analysis; Sequence analysis confirms that recombinant plasmid contains Infection of Toxoplasma Gondii GRA6 genetic fragment and the P30 GFP fragment of series connection, and sequence is entirely true: ATG GCA GCA GAC AGC GGT GGT GTT AAG CAG ACC CCT TCG GAA ACC GGT TCG AGC GGTGGA CAG CAA GAA GCA GTG GGG ACC ACT GAA GAC TAT GTC AAC TCT TCG GCG ATG GGCGGT GGC CAA GGC GAC TCG TTA GCT GAA GAT GAT ACA ACC TCC GAA GCG GCG GAG GGCGAC GTT GAC CCT TTT CCC GTG CTG GCG AAT GAG GGG AAG TCG GAG GCG CGT GGC CCGTCG CTC GAG GAA AGA ATC GAA GAA CAG GGC ACA AGA CGA CGT TAC TCC TCT GTT CAAGAA CCA CAA GCG AAG GTG CCT AGC AAA CGA ACA CAG AAA CGC CAC AGAGGA TCCCAAGTT GTC ACC TGC CCA CAT AAA AAA TCG ACA GCC GCG GTC ATT CTC ACA CCG ACG GAGAAC CAC TTC ACT CTC AAG TGC CCT AAA ACA GCG CTC ACA GAG CCT CCC ACT CTT GCGTAC TCA CCC AAC AGG CAA ATC TGC CCA GCG GGT ACT ACA AGT AGC TGT ACA TCA AAGGCT GTA ACA TTG AGC TCC TTG ATT CCT GAA GCA GAA GAT AGC TGG TGG ACG GGG GATTCT GCT AGT CTG GAC ACG GCA GGC ATC AAA CTC ACA GTT CCA ATC GAG AAG TTC CCCGTG ACA ACG CAG ACG TTT GTG GTC GGT TGC ATC AAG GGA GAC GAC GCA CAG AGC TGTATG GTC ACG GAG ACA GTA CAA GCC AGA GCC TCA TCG GTC GTC AAT AAT GTC GCA AGGTGC TCC TAC GGT GCA GAC AGC ACT CTT GGT CCT GTC AAG GTG TCT GCG GAA GAA CCCACT ACA ATG ACC CTC GTG TGC GGG AAA GAT GGA GTC AAA GTT CCT CAA GAC AAC AATCAG TAC TGT TCC GGG ACG ACG CTG ACT GGT TGC AAC GAG AAA TCG TTC AAA GAT ATTTTG CCA AAA TTA ACT GAG AAC CCG TGG CAG GGT AAC GCT TCG AGT GAT AAG GGT GCCACG CTA ACG ATC AAG AAG GAA GCA TTT CCA GCC GAG TCA AAA AGC GTC ATT ATT GGATGC ACA GGG GGA TCG CCT GAG AAG CAT CAC TGT ACC GTG AAA CTG GAG TTT GCC GGGGCT GCA GGG TCA GCA AAA TCG GCT GCG GGA TAA
The expression of recombinant plasmid toxoplasma gondii GRA6 albumen and the proteic fusion rotein of P30 that make up; Be connected by 2 amino acid of glycine (Gly) and Serine (Ser) between the two; wherein toxoplasma gondii GRA6 albumen is at the N of fusion rotein end, and P30 albumen is at the C of fusion rotein end.：Met Ala Ala Asp Ser Gly Gly Val Lys Gln Thr Pro Ser Glu Thr Gly Ser Ser GlyGly Gln Gln Glu Ala Val Gly Thr Thr Glu Asp Tyr Val Asn Ser Ser Ala Met GlyGly Gly Gln Gly Asp Ser Leu Ala Glu Asp Asp Thr Thr Ser Glu Ala Ala Glu GlyAsp Val Asp Pro Phe Pro Val Leu Ala Asn Glu Gly Lys Ser Glu Ala Arg Gly ProSer Leu Glu Glu Arg Ile Glu Glu Gln Gly Thr Arg Arg Arg Tyr Ser Ser Val GlnGlu Pro Gln Ala Lys Val Pro Cys Lys Arg Thr Gln Lys Arg His Arg Gly Ser GlnVal Val Thr Cys Pro His Lys Lys Ser Thr Ala Ala Val Ile Leu Thr Pro Thr GluAsn His Phe Thr Leu Lys Cys Pro Lys Thr Ala Leu Thr Glu Pro Pro Thr Leu AlaTyr Ser Pro Asn Arg Gln Ile Cys Pro Ala Gly Thr Thr Ser Ser Cys Thr Ser LysAla Val Thr Leu Ser Ser Leu Ile Pro Glu Ala Glu Asp Ser Trp Trp Thr Gly AspSer Ala Ser Leu Asp Thr Ala Gly Ile Lys Leu Thr Val Pro Ile Glu Lys Phe ProVal Thr Thr Gln Thr Phe Val Val Gly Cys Ile Lys Gly Asp Asp Ala Gln Ser CysMet Val Thr Glu Thr Val Gln Ala Arg Ala Ser Ser Val Val Asn Asn Val Ala ArgCys Ser Tyr Gly Ala Asp Ser Thr Leu Gly Pro Val Lys Val Ser Ala Glu Glu ProThr Thr Met Thr Leu Val Cys Gly Lys Asp Gly Val Lys Val Pro Gln Asp Asn AsnGln Tyr Cys Ser Gly Thr Thr Leu Thr Gly Cys Asn Glu Lys Ser Phe Lys Asp IleLeu Pro Lys Leu Thr Glu Asn Pro Trp Gln Gly Asn Ala Ser Ser Asp Lys Gly AlaThr Leu Thr Ile Lys Lys Glu Ala Phe Pro Ala Glu Ser Lys Ser Val Ile Ile GlyCys Thr Gly Gly Ser Pro Glu Lys His His Cys Thr Val Lys Leu Glu Phe Ala GlyAla Ala Gly Ser Ala Lys Ser Ala Ala Gly：
Transformant is seeded to contains 3ml LB substratum (containing kanamycin 60 μ g/ml) in vitro, 37 ℃ of shaking culture 3h, add IPTG to final concentration 0.5mmol/L, continue shaking culture and induce 6h, centrifugal collection thalline carries out SDS-PAGE and detects, recon is expressed relative molecular weight and is about 39000 fusion rotein, and expression amount is about 28%, and contrast bacterium BL21 (DE3) does not have this protein band.The purifying of expressed fusion protein:
1) ultrasonic degradation of expressed fusion protein engineering bacteria
Centrifugal (8000rpm, 10min, 4 ℃) receives bacterium with the engineering bacteria of abduction delivering fusion rotein, thalline is resuspended in the lysate (50mmol/L Tris-HCl pH8.14,10mmol/L EDTA, 10mmol/L DTT, 5% glycerine) of original fluid 1/10 volume, ice-bath ultrasonic is broken bacterium 10min, centrifugal (12000rpm, 20min, 4 ℃) collecting precipitation inclusion body.
2) cracking of inclusion body
Inclusion body suspends with 0.5%SKL (with 50mmol/L Tris-HCl pH8.14,0.5mmol/L EDTA, the preparation of 0.25mmol/L DTT balance liquid) solution, room temperature cracking inclusion body 1h, centrifugal (12000rpm, 20min, 4 ℃), collect supernatant, in the dialysis tubing of packing into 1000ml balance liquid (50mmol/L Tris-HCl pH8.14,0.5mmol/L EDTA, 0.25mmol/L DTT) is dialysed.4 ℃ of dialysed overnight are changed dialyzate next day 2 times, each 1000ml.Centrifugal (8000rpm, 20min, 4 ℃) collects DEAE-Sepharose FF anion column purifying on the supernatant.
3) DEAE-Sepharose FF anion column purifying
DEAE-Sepharose FF anion column is connected to the normal pressure chromatographic system, earlier with balance liquid (50mmol/LTris-HCl pH8.14,0.5mmol/L EDTA, 0.25mmol/L DTT) flushing balance, to go up the cracking supernatant of step acquisition then and directly go up sample, last sample flow velocity is 1.5ml/min.The peak is passed in collection.Behind the last sample with balance liquid flushing, then successively with contain 50,100,200,300, the balance liquid eluted protein of 1000mmol/L NaCl, collect each elution peak albumen.Pass this peak, peak and each elution peak albumen with the 12%SDS-PAGE detection, determine that component contains fusion rotein.The fusion rotein of purifying is used as the Detection of antigen toxoplasma antibody:
Wrap by elisa plate behind fusion rotein usefulness carbonate (pH9.6) doubling dilution of 50mmol/L with purifying, the indirect enzyme-linked immunosorbent method detects known resisting toxoplasmosis IgM (or IgG) positive serum and normal human serum, the result shows, fusion rotein can react with resisting toxoplasmosis IgM (or IgG) positive serum positive serum,, do not illustrate that this fusion rotein has antigenicity and specificity preferably with the normal human serum reaction.
Same with this fusion rotein of horseradish peroxidase (HRP) mark, detect resisting toxoplasmosis IgM or IgG antibody with pouncing on the method that obtains, higher susceptibility and specificity are arranged.This fusion rotein detects resisting toxoplasmosis IgM or IgG antibody as antigen with golden mark method, and higher susceptibility and specificity are also arranged.The advantage that the present invention compared with prior art has
Mostly the toxoplasma protein antigen of China's use at present is to cultivate viral extract, contains a plurality of protein products, and antigen-specific is not strong, easily produces false positive.External toxoplasma gondii total length GRA6 albumen and the P30 albumen that uses has stronger antigenicity, its corresponding antibody recall rate is higher in arch insect infection person's serum, but making the Detection of antigen toxoplasma antibody with total length GRA6 albumen and P30 albumen has two shortcomings: the one, and false positive can appear.The 2nd, when detecting resisting toxoplasmosis IgM, need mark GRA6 albumen and two albumen of P30 albumen with prize law.
We select the part fragment that antigenicity is strong, specificity is good in toxoplasma gondii GRA6 albumen and the P30 albumen respectively, utilize genetic engineering technique to express both fusion roteins, and the GRA6 albumen of expression and the proteic fusion rotein of P30 have more advantage:
When 1. making Detection of antigen resisting toxoplasmosis IgM serum, no longer need to prepare respectively this two kinds of albumen, also do not need to adjust two antigenic usage ratios, so application is convenient and cost is lower with these two albumen.
2. when detecting resisting toxoplasmosis IgM, only need this a kind of fusion rotein of enzyme labelling, no longer need two albumen of mark respectively with prize law.Therefore, when detection antibody needed a plurality of proteantigen, preparation multivalence fusion rotein antigen was one of ideal developing direction.
3. the expression toxoplasma gondii GRA6 albumen that makes up of this paper and the engineering bacteria of P30 fusion protein, expression amount can reach 28% of thalline soluble proteins, exists with inclusion body and two kinds of forms of solubility, be easy to purifying, but large-scale purification prepares this fusion rotein.Do not see Table at present the report that reaches this fusion rotein.
Description of drawings
The invention will be further described below with reference to accompanying drawing:
Fig. 1 carries out analytical results with multiple molecular biology software to the epitope in the toxoplasma gondii GRA6 albumen.The result shows, contains strong wetting ability epitope at 152 amino acid of proteic the 43rd amino acid to the of toxoplasma gondii GRA6, i.e. the position that arrow indicates in the figure.
Fig. 2 carries out analytical results with multiple molecular biology software to the epitope in the toxoplasma gondii P30 albumen.The result shows, contains strong wetting ability epitope at 313 amino acid of proteic the 56th amino acid to the of toxoplasma gondii P30, i.e. the position that arrow indicates in the figure.
Fig. 3 is Agarose gel detection pcr amplification toxoplasma gondii GRA6 albumen and the proteic gene fragment of P30 with 1.2%.The GRA6 gene fragment of 1:352bp; The P30 gene fragment of 2:795bp; M: nucleic acid standard molecular weight (TaKaRa DL2000).
Fig. 4 is the construction of recombinant plasmid schema of expressing toxoplasma gondii GRA6 and P30 fusion rotein.
Fig. 5 is the pcr amplification product with 6 transformants of Agarose gel detection of 1.2%, have 4 (the 1st, 2,4, No. 6 recons) to amplify the target gene fragment of 1132bp in 6 transformants, 2 transformants (the 3rd, No. 5 recon) do not amplify this gene fragment.C: contain the contrast bacterium of plasmid pET28a (+), M: nucleic acid standard molecular weight (TaKaRa DL2000).
Fig. 6 is the SDS-PAGE analytical results of expressing toxoplasma gondii GRA6 and P30 fusion rotein reorganization bacterium.1～No. 6: 1,2,4, No. 6 reorganization bacterium are all expressed relative molecular weight and are about 39000 fusion rotein, i.e. the position that arrow indicates in the figure; 3, No. 52 recons expressed fusion protein not.C: contrast bacterium E.coli BL21 (DE3).
Fig. 7 is the SDS-PAGE analytical results of expressing toxoplasma gondii GRA6 and P30 fusion rotein purifying front and back.M: low molecular weight protein (LMWP) standard (Pharmacia); 1: contrast bacterium BL21 (DE3); 2: the engineering bacteria of expressing GRA6 and P30 fusion rotein; 3: engineering bacteria ultrasonic degradation supernatant; 4: with the GRA6 and the P30 fusion rotein fusion rotein of DEAE-Sepharose FF anion column purifying.
Embodiment
The detailed description of embodiment of the present invention:
Toxoplasma gondii GRA6 albumen and P30 protein fusion expression
With PCR method amplification toxoplasma gondii GRA6 protein gene fragment and P30 protein gene fragment.To same plasmid pET28a (+) interior NcoI/BamHI and BamHI/EcoRI site, both are cascaded these two gene fragment clones, and translation framework unanimity, a fusion rotein can be expressed.With recombinant plasmid transformed e. coli bl21 (DE3), screening has obtained to efficiently express the engineering bacteria of this fusion rotein, and the fusion rotein of expression accounts for about 28% of tropina total amount, exists with inclusion body and two kinds of forms of solubility.Materials and methods
1. bacterial classification and plasmid: host bacterium BL21 (DE3) and expression vector pET28a (+) are U.S. Novagen company product.
2. molecular biology reagent: restriction enzyme NcoI, BamHI, EcoRI, and the T4 dna ligase be TaKaRa company product.Plasmid purification test kit and the test kit that reclaims dna fragmentation in the sepharose are German QIAGEN company product.DTT and IPTG are Promega company product.Other reagent is import or homemade analytical reagent.
3. gene fragment is synthetic: helped synthetic by Dalian TaKaRa company.
The enzyme of gene clone method: DNA cut, connection, electrophoresis; The extraction of plasmid, conversion; General molecular cloning methods such as proteic SDS-PAGE analysis carry out according to a conventional method.Other test kit by specification is operated.
5.DNA sequential analysis: with QIAGEN company plasmid purification test kit plasmid purification, with the full-automatic sequenator order-checking of DNA.The screening of 1. toxoplasma gondii GRA6 albumen and P30 proteantigen epi-position as a result:
Utilize softwares such as ANTHEWIN, by the proteic whole aminoacid sequence (GeneBank of Computer Analysis toxoplasma gondii GRA6, closing number: L33814) with the proteic whole aminoacid sequence (GeneBank of P30, closing number: S73634), the strong antigen epi-position that filters out in the toxoplasma gondii GRA6 albumen is positioned at 152 amino acid (see figure 1)s of the 43rd amino acid to the; Strong antigen epi-position in the P30 albumen is positioned at 313 amino acid (see figure 2)s of the 56th amino acid to the.2. the gene clone of toxoplasma gondii GRA6 albumen and P30 proteantigen epi-position:
Select design PCR primer in the both sides of the dna sequence dna of shape worm GRA6 proteantigen epi-position.The upstream primer of design is GRA6P1 (547-565bp): 5 '-GCGAGTCA
CCATGGCAGCAGACAGCGGTGGTG-3 '; Downstream primer is GRA6P2 (856-876bp): 5 '-CGC
GGATCCTCTGTGGCGTTTCTGTGTTCG-3 '.On upstream primer, increased NcoI restriction enzyme site (following setting-out part), and increased by 8 protection bases, be beneficial to the cutting of NcoI enzyme at 5 ' weak point.On downstream primer, increase BamHI restriction enzyme site (following setting-out part).
Select design PCR primer in the both sides of the dna sequence dna of shape worm P30 proteantigen epi-position.The upstream primer of design is P30P3 (166-184bp): 5 '-CTG
GGATCCCAAGTTGTCACCTGCCCA-3 '; Downstream primer is P30P4 (922-939bp): 5 '-GTC
GAATTCTTATCCCGCAGCCGATTTTGC-3 '.On upstream primer, increased BamHI restriction enzyme site (following setting-out part), and increased by 3 protection bases, be beneficial to the cutting of BamHI enzyme at 5 ' weak point.On downstream primer, increase EcoRI restriction enzyme site (following setting-out part) and give terminator codon (italic).
Get the toxoplasma gondii 100 μ l (Agricultural University Of Nanjing provides) that mouse is cultivated, centrifugal, the collecting precipitation polypide suspends with 200 μ l TE solution (50mmol/L Tris-HCl pH8.0,0.5mmol/L EDTA), add 100 μ l Proteinase Ks (10mg/ml), put 56 ℃ of water-baths 4 hours.With phenol/chloroform method purifying bow-shaped worm dna, the bow-shaped worm dna that obtains is dissolved in the 20 μ l deionized waters, put-20 ℃ frozen standby.
Bow-shaped worm dna with above-mentioned purification is a template, with the gene fragment of primer GRA6P1 and GRA6P2 pcr amplification toxoplasma gondii GRA6 proteantigen epi-position, with the gene fragment of primer P30P3 and P30P4 pcr amplification toxoplasma gondii P30 proteantigen epi-position.Reaction density is: bow-shaped worm dna is template 2 μ l, primer P1, P2 each 1 μ l, 10x buffer5.0 μ l, 2.5mmol/L dNTP 4.0 μ l, Taq archaeal dna polymerase 0.5 μ l (2.5U), deionized water 36.5 μ l, cumulative volume 50 μ l.Amplification condition is: 94 ℃ 30 seconds, 65 ℃ 30 seconds, 72 ℃ 60 seconds, 35 circulations; Last 72 ℃ were extended 7 minutes.Respectively get PCR product 5 μ l, detect with 1.2% agarose gel electrophoresis, the result expands the GRA6 gene fragment that 352bp and the P30 gene fragment (Fig. 3) of 795bp.Electrophoresis reclaims, the gene fragment of purifying amplification, is dissolved in the 20 μ l deionized waters, put-20 ℃ frozen standby.3. expressed fusion protein construction of recombinant plasmid:
Extract plasmid pET28a (+) (U.S. Novagen company product),, reclaim the big fragment of plasmid that enzyme is cut behind the electrophoresis, be dissolved in the 20 μ l deionized waters with NcoI and EcoRI double digestion.With NcoI and BamHI double digestion toxoplasma gondii GRA6 gene fragment, its 5 ' formation NcoI sticky end, 3 ' end is dissolved in the deionized water after forming the recovery of BamHI sticky end electrophoresis.With the P30 protein gene fragment of EcoRI and BamHI double digestion purifying, electrophoresis is dissolved in the deionized water after reclaiming.
Get above-mentioned three kinds of enzymes and cut the back dna fragmentation, the volumetric molar concentration mixing such as press, in same centrifuge tube, connect (putting 16 ℃ of connections spends the night) with the T4 dna ligase, the GRA6 gene fragment is connected with the P30 gene fragment be inserted into (the structure flow process is seen Fig. 4) between carrier pET28a (+) the interior NcoI and EcoRI site, both translate the framework unanimity, express a fusion rotein.4. the screening of recombinant plasmid:
The recombinant plasmid transformed that the last step was connected arrives e. coli bl21 (DE3), and the converted product coating is contained on the solid LB substratum of kantlex (60 μ g/ml), puts 37 ℃ of overnight incubation.6 transformant bacterium colonies of random choose next day and a contrast bacterium that contains plasmid pET28a (+) are inoculated into respectively and contain 4ml liquid LB substratum (containing kantlex 60 μ g/ml) and in vitro, put 37 ℃ of shaking culture 6h, get bacterium liquid 1ml, centrifugal receipts bacterium.Use 50 μ l deionized water suspension thalline respectively, boiling water boils 5min, centrifugal, and (4 ℃, 12000rpm) 5min gets supernatant (in plasmid is arranged) 2 μ l as pcr template.It is right to form primer with primer GRA6P1 and primer P30P4, is that template is carried out the PCR evaluation with the plasmid that extracts, and contains the recombinant plasmid of toxoplasma gondii GRA6 gene fragment and P30 protein gene fragment tandem gene, should amplify a 1132bp gene fragment.
The PCR reaction density is: plasmid template 2 μ l, primer GRA6P1 and primer P30P4 each 1 μ l, 10x buffer5.0 μ l, 2.5mmol/L dNTP 4.0 μ l, Taq archaeal dna polymerase 0.5 μ l (2.5U), deionized water 36.5 μ l, cumulative volume 50 μ l.Amplification condition is: 94 ℃ 30 seconds, 65 ℃ 30 seconds, 72 ℃ 60 seconds, 35 circulations; Last 72 ℃ were extended 7 minutes.Get pcr amplification product 5 μ l, Agarose gel detection with 1.2%, the result, have 4 (the 1st, 2,4, No. 6 recons) to amplify the target gene fragment (see figure 5) of 1132bp in 6 transformants, 2 transformants (the 3rd, No. 5 recon) and the contrast bacterium that contains plasmid pET28a (+) do not amplify this gene fragment.Tentative confirmation has 4 transformants to contain placed in-line toxoplasma gondii GRA6 gene fragment and P30 protein gene fragment.5. the Screening and Identification of expressed fusion protein engineering bacteria:
Above-mentioned 6 transformants are seeded to respectively contain 3ml LB substratum (containing kanamycin 60 μ g/ml) in vitro, 37 ℃ of shaking culture 3h add IPTG to final concentration 0.5mmol/L, continue shaking culture and induce 6h, and centrifugal collection thalline carries out SDS-PAGE and detects.Electrophoresis detection shows (Fig. 6), and 4 PCR evaluation male recons are all expressed relative molecular weight and are about 39000 fusion rotein, and expression amount is about 28%, and contrast bacterium and 2 PCR identify that negative recons all do not have this protein band.Obtained the engineering bacteria of high expression level toxoplasma gondii GRA6 gene fragment and P30 protein gene fragment fusion rotein.6.DNA The sequencing results:
No. 1 transformant of destination protein will be expressed; Extract plasmid and carry out determined dna sequence; GRA6 genetic fragment in the recombinant plasmid and the dna sequence dna of P30 genetic fragment are entirely true, and the result is as follows: ATG GCA GCA GAC AGC GGT GGT GTT AAG CAG ACC CCT TCG GAA ACC GGT TCG AGC GGTGGA CAG CAA GAA GCA GTG GGG ACC ACT GAA GAC TAT GTC AAC TCT TCG GCG ATG GGCGGT GGC CAA GGC GAC TCG TTA GCT GAA GAT GAT ACA ACC TCC GAA GCG GCG GAG GGCGAC GTT GAC CCT TTT CCC GTG CTG GCG AAT GAG GGG AAG TCG GAG GCG CGT GGC CCGTCG CTC GAG GAA AGA ATC GAA GAA CAG GGC ACA AGA CGA CGT TAC TCC TCT GTT CAAGAA CCA CAA GCG AAG GTG CCT AGC AAA CGA ACA CAG AAA CGC CAC AGAGGA TCCCAAGTT GTC ACC TGC CCA CAT AAA AAA TCG ACA GCC GCG GTC ATT CTC ACA CCG ACG GAGAAC CAC TTC ACT CTC AAG TGC CCT AAA ACA GCG CTC ACA GAG CCT CCC ACT CTT GCGTAC TCA CCC AAC AGG CAA ATC TGC CCA GCG GGT ACT ACA AGT AGC TGT ACA TCA AAGGCT GTA ACA TTG AGC TCC TTG ATT CCT GAA GCA GAA GAT AGC TGG TGG ACG GGG GATTCT GCT AGT CTG GAC ACG GCA GGC ATC AAA CTC ACA GTT CCA ATC GAG AAG TTC CCCGTG ACA ACG CAG ACG TTT GTG GTC GGT TGC ATC AAG GGA GAC GAC GCA CAG AGC TGTATG GTC ACG GAG ACA GTA CAA GCC AGA GCC TCA TCG GTC GTC AAT AAT GTC GCA AGGTGC TCC TAC GGT GCA GAC AGC ACT CTT GGT CCT GTC AAG GTG TCT GCG GAA GAA CCCACT ACA ATG ACC CTC GTG TGC GGG AAA GAT GGA GTC AAA GTT CCT CAA GAC AAC AATCAG TAC TGT TCC GGG ACG ACG CTG ACT GGT TGC AAC GAG AAA TCG TTC AAA GAT ATTTTG CCA AAA TTA ACT GAG AAC CCG TGG CAG GGT AAC GCT TCG AGT GAT AAG GGT GCCACG CTA ACG ATC AAG AAG GAA GCA TTT CCA GCC GAG TCA AAA AGC GTC ATT ATT GGATGC ACA GGG GGA TCG CCT GAG AAG CAT CAC TGT ACC GTG AAA CTG GAG TTT GCC GGGGCT GCA GGG TCA GCA AAA TCG GCT GCG GGA TAA
The purified material of express recombinant toxoplasma gondii fusion rotein and method 1. main agents
DEAE-SepharoseFF negatively charged ion gel is a Pharmacia company product, and IPTG, DTT are Promega company product.Other reagent is homemade or the import analytical reagent.2. express the ultrasonic degradation of toxoplasma gondii fusion rotein engineering bacteria
Centrifugal (the 8000rpm of engineering bacteria with the expression toxoplasma gondii fusion rotein cultivated, 10mins, 4 ℃), abandon supernatant, thalline is resuspended in the lysate (50mmol/L Tris-HCl pH8.0,10mmol/L EDTA, 10mmol/L DTT, 5% glycerine) of original fluid 1/10 volume, ice-bath ultrasonic is broken bacterium 10mins, centrifugal (12000rpm, 20mins, 4 ℃) collecting precipitation inclusion body.3. the cracking of inclusion body
Inclusion body suspends with 0.5%SKL (with 50mmol/L Tris-HCl pH8.14,0.5mmol/L EDTA, the preparation of 0.25mmol/L DTT balance liquid) solution, room temperature cracking inclusion body 1h, centrifugal (12000rpm, 20min, 4 ℃), collect supernatant, in the dialysis tubing of packing into 1000ml balance liquid (50mmol/L Tris-HCl pH8.14,0.5mmol/L EDTA, 0.25mmol/L DTT) is dialysed.4 ℃ of dialysed overnight are changed dialyzate next day 2 times, each 1000ml.Centrifugal (8000rpm, 20min, 4 ℃) collects DEAE-Sepharose FF anion column purifying on the supernatant.4.DEAE-Sepharose FF anion column purifying
DEAE-Sepharose FF anion column is connected to the normal pressure chromatographic system, earlier with balance liquid (50mmol/LTris-HCl pH8.14,0.5mmol/L EDTA, 0.25mmol/L DTT) flushing balance, to go up the cracking supernatant of step acquisition then and directly go up sample, last sample flow velocity is 1.5ml/min.The peak is passed in collection.Behind the last sample with balance liquid flushing, then successively with contain 50,100,200,300, the balance liquid eluted protein of 1000mmol/L NaCl, collect each elution peak albumen.Pass this peak, peak and each elution peak albumen with the 12%SDS-PAGE detection, determine that component contains fusion rotein.1.DEAE-Sepharose FF anion column purifying toxoplasma gondii fusion rotein as a result
Each the peak albumen that passes peak and different concns NaCl wash-out is carried out SDS-PAGE analyze demonstration, toxoplasma gondii fusion rotein (molecular weight 39000) mainly is present in the 300mmol/L NaCl elution peak, and very high purity is arranged; Also tangible worm fusion rotein in 200mmol/L NaCl elution peak, but contain other protein peak; There is not this protein band (see figure 7) in other concentration NaCl elution peak.
The evaluation and the application of purification of Recombinant toxoplasma gondii fusion rotein
The recombinant toxoplasma fusion rotein of purifying is used as antigen, and indirect ELISA method detects toxoplasma antibody (IgM or IgG) positive and negative serum, with specificity and the antigenicity of identifying this recombinant protein antigen.Experimental result shows that this recombinant protein has excellent specificity and antigenicity, can be used as the Detection of antigen toxoplasma antibody.Material and method
1. resisting toxoplasmosis IgM positive serum: provide by units such as Nanjing Military Command hospital generals.
2. integrated enzyme reaction material: elisa plate is that 96 orifice plates are produced in Shenzhen, and the mouse-anti people μ chain monoclonal antibody of horseradish peroxidase (HRP) mark is available from Sigama company.Other material is the conventional material of integrated enzyme reaction.
3.ELISA test: adopt the IgM antibody in the indirect ELISA detection serum.Basic step is: dilute the recombinant protein bag by elisa plate with 50mmol/L carbonate solution (pH9.6), and every hole 100 μ l, 4 ℃ are spent the night.Inferior daily confining liquid (10mmol/L phosphate buffered saline buffer, pH7.4,10% lowlenthal serum, 20% calf serum, 0.5%casein, 0.05% sulphur sulphur mercury, 5% sucrose) sealing, every hole 130 μ l, 37 ℃ of 1h (or 4 ℃ spend the night).With resisting toxoplasmosis IgM the moon to be measured, positive serum sample diluent (10mmol/L phosphate buffered saline buffer, pH7.4,10% lowlenthal serum, 20% calf serum, 0.5% casein, 0.05% sulphur sulphur mercury, 0.5mmol/L NaCl) after the dilution in 1: 100, add in the enzyme linked plate holes after the sealing every hole 100 μ l respectively, each sample adds 2 holes, 37 ℃ of reaction 30min are with PBST liquid (10mmol/L phosphate buffered saline buffer, pH7.4,0.5% tween 20) wash 5 times after, the anti-people μ chain monoclonal antibody that adds the horseradish peroxidase-labeled of dilution in 1: 5000, every hole 100 μ l, 37 ℃ of reaction 30min, PBST washes 5 times, add substrate TMB solution 100 μ l, 37 ℃ of lucifuge colour developing 10min add 50 μ l 4N sulfuric acid mixing termination reactions, measure the A450 value with enzyme connection instrument.1. indirect ELISAs detect the Toxoplasma Gondi IgM antibody in the serum as a result
With the toxoplasma gondii GRA6 of purifying and 1: 500～1: 8000 doubling dilution bag of P30 fusion rotein by elisa plate, detect known 1 part of resisting toxoplasmosis IgM positive serum and 1 portion of normal human serum, the result shows (seeing Table 1), fusion rotein can react with resisting toxoplasmosis IgM positive serum,, do not illustrate that tentatively this fusion rotein has antigenicity and specificity preferably with the normal human serum reaction.
The ELISA experimental result of table 1 fusion rotein (A450 value) bag is by 1: 500 1: 1,000 1: 2,000 1: 4,000 1: 8000 resisting toxoplasmosis IgM of fusion rotein positive serum, 1.632 1.216 0.970 0.541 0.216 normal human serums 0.120 0.052 0.036 0.022 0.027
The fusion rotein of purifying and the bovine serum albumin of known different concns (the 5th part) co-electrophoresis, colour developing back are compared, determine that the recombination fusion protein concentration of purifying is about 2mg/ml.By elisa plate, detect known 6 parts of resisting toxoplasmosis negative serums and 6 parts of resisting toxoplasmosis positive serums with 1: 1000 dilution back of 50mmol/L carbonate solution (pH9.6) bag.The result shows that 6 parts of resisting toxoplasmosis IgM negative serums all do not develop the color, and color reaction all appears in 6 parts of resisting toxoplasmosis IgM positive serums, illustrates that this fusion rotein has antigenicity and specificity preferably.Measure the A450 value (seeing Table 2) of each hole sample with enzyme connection instrument.Detected 184 portions of normal human serums that preserve in the laboratory in addition again, their A450 value has confirmed further that all less than 0.05 this fusion rotein has specificity preferably.
Table 2 purified fusion protein ELISA experimental result (A450) * 123456789 10 11 120.051 0.043 0.028 0.036 0.436 0.530 0.703 0.805 0.949 0.698 1.319 1.2070.048 0.050 0.030 0.040 0.419 0.571 0.730 0.814 0.930 0.718 1.401 1.216*: 1～6: resisting toxoplasmosis IgM negative serum, 7～12: resisting toxoplasmosis IgM positive serum
Recombinant toxoplasma fusion rotein sequence table＜110〉Li Yuexi＜120〉recombinant human toxoplasma gondii fusion roteins and preparation method thereof, use＜160〉2＜210〉1＜211〉371＜212〉PRT＜213〉artificial sequence＜220〉＜223〉1 one kinds of recombinant toxoplasma fusion roteins, be the fusion rotein of toxoplasma gondii GRA6 albumen n end from 152 amino acid whose 110 amino acid of the 43rd amino acid to the and 313 amino acid whose 258 amino acid series connection formation of proteic the 56th amino acid to the of P30,110 amino acid of GRA6 albumen n end are held at fusion rotein N, proteic 258 amino acid of P30 are at the C of fusion rotein end, be connected by 2 amino acid of glycine (Gly) and Serine (Ser) between the two, the N end of fusion rotein has increased by 1 egg base acid (Met), 371 amino acid of total length.＜400〉1Met Ala Ala Asp Ser Gly Gly Val Lys Gln Thr Pro Ser Glu Thr Gly 15 10 15Ser Ser Gly Gly Gln Gln Glu Ala Val Gly Thr Thr Glu Asp Tyr Val
20 25 30Asn?Ser?Ser?Ala?Met?Gly?Gly?Gly?Gln?Gly?Asp?Ser?Leu?Ala?Glu?Asp
35 40 45Asp?Thr?Thr?Ser?Glu?Ala?Ala?Glu?Gly?Asp?Val?Asp?Pro?Phe?Pro?Val
50 55 60Leu?Ala?Asn?Glu?Gly?Lys?Ser?Glu?Ala?Arg?Gly?Pro?Ser?Leu?Glu?Glu65 70 75 80Arg?Ile?Glu?Glu?Gln?Gly?Thr?Arg?Arg?Arg?Tyr?Ser?Ser?Val?Gln?Glu
85 90 95Pro?Gln?Ala?Lys?Val?Pro?Cys?Lys?Arg?Thr?Gln?Lys?Arg?His?Arg?Gly
100 105 110Ser?Gln?Val?Val?Thr?Cys?Pro?His?Lys?Lys?Ser?Thr?Ala?Ala?Val?Ile
115 120 125Leu?Thr?Pro?Thr?Glu?Asn?His?Phe?Thr?Leu?Lys?Cys?Pro?Lys?Thr?Ala
130 135 140Leu?Thr?Glu?Pro?Pro?Thr?Leu?Ala?Tyr?Ser?Pro?Asn?Arg?Gln?Ile?Cys145 150 155 160Pro?Ala?Gly?Thr?Thr?Ser?Ser?Cys?Thr?Ser?Lys?Ala?Val?Thr?Leu?Ser
165 170 175Ser?Leu?Ile?Pro?Glu?Ala?Glu?Asp?Ser?Trp?Trp?Thr?Gly?Asp?Ser?Ala
180 185 190Ser?Leu?Asp?Thr?Ala?Gly?Ile?Lys?Leu?Thr?Val?Pro?Ile?Glu?Lys?Phe
195 200 205Pro?Val?Thr?Thr?Gln?Thr?Phe?Val?Val?Gly?Cys?Ile?Lys?Gly?Asp?Asp
210 215 220Ala?Gln?Ser?Cys?Met?Val?Thr?Glu?Thr?Val?Gln?Ala?Arg?Ala?Ser?Ser225 230 235 240Val?Val?Asn?Asn?Val?Ala?Arg?Cys?Ser?Tyr?Gly?Ala?Asp?Ser?Thr?Leu
245 250 255Gly?Pro?Val?Lys?Val?Ser?Ala?Glu?Glu?Pro?Thr?Thr?Met?Thr?Leu?Val
260 265 270Cys?Gly?Lys?Asp?Gly?Val?Lys?Val?Pro?Gln?Asp?Asn?Asn?Gln?Tyr?Cys
275 280 285Ser?Gly?Thr?Thr?Leu?Thr?Gly?Cys?Asn?Glu?Lys?Ser?Phe?Lys?Asp?Ile
290 295 300Leu?Pro?Lys?Leu?Thr?Glu?Asn?Pro?Trp?Gln?Gly?Asn?Ala?Ser?Ser?Asp305 310 315 320Lys?Gly?Ala?Thr?Leu?Thr?Ile?Lys?Lys?Glu?Ala?Phe?Pro?Ala?Glu?Ser
325 330 335Lys?Ser?Val?Ile?Ile?Gly?Cys?Thr?Gly?Gly?Ser?Pro?Glu?Lys?His?His
340 345 350Cys?Thr?Val?Lys?Leu?Glu?Phe?Ala?Gly?Ala?Ala?Gly?Ser?Ala?Lys?Ser
355 360 365Ala?Ala?Gly
370＜210〉2＜211〉1116＜212〉DNA＜213〉artificial sequence＜220〉＜221〉CDS＜222〉(1) ... (1116)＜220〉＜221〉mis-feature＜222〉(1) ... the initiator codon that increases when (3)＜223〉increasing the GRA6 gene fragment.＜220〉＜221〉mis-feature＜222〉(4) ... (333)＜223〉GRA6 gene fragment gene fragment order.＜220〉＜221〉mis-feature＜222〉(334) ... (339)＜223〉the BamHI restriction enzyme site of connection GRA6 fragment gene and P30 gene fragment.＜220〉＜221〉mis-feature＜222〉(340) ... (1116)＜223〉P30 gene fragment.<400>2ATG?GCA?GCA?GAC?AGC?GGT?GGT?GTT?AAG?CAG?ACC?CCT?TCG?GAA?ACC?GGT?TCG?AGC?GGT?GGA 60Met?Ala?Ala?Asp?Ser?Gly?Gly?Val?Lys?Gln?Thr?Pro?Ser?Glu?Thr?Gly?Ser?Ser?Gly?Gly1 5 10 15 20CAG?CAA?GAA?GCA?GTG?GGG?ACC?ACT?GAA?GAC?TAT?GTC?AAC?TCT?TCG?GCG?ATG?GGC?GGT?GGC 120Gln?Gln?Glu?Ala?Val?Gly?Thr?Thr?Glu?Asp?Tyr?Val?Asn?Ser?Ser?Ala?Met?Gly?Gly?Gly
25 30 35 40CAA?GGC?GAC?TCG?TTA?GCT?GAA?GAT?GAT?ACA?ACC?TCC?GAA?GCG?GCG?GAG?GGC?GAC?GTT?GAC 180Gln?Gly?Asp?Ser?Leu?Ala?Glu?Asp?Asp?Thr?Thr?Ser?Glu?Ala?Ala?Glu?Gly?Asp?Val?Asp
45 50 55 60CCT?TTT?CCC?GTG?CTG?GCG?AAT?GAG?GGG?AAG?TCG?GAG?GCG?CGT?GGC?CCG?TCG?CTC?GAG?GAA 240Pro?Phe?Pro?Val?Leu?Ala?Asn?Glu?Gly?Lys?Ser?Glu?Ala?Arg?Gly?Pro?Ser?Leu?Glu?Glu
65 70 75 80AGA?ATC?GAA?GAA?CAG?GGC?ACA?AGA?CGA?CGT?TAC?TCC?TCT?GTT?CAA?GAA?CCA?CAA?GCG?AAG 300Arg?Ile?Glu?Glu?Gln?Gly?Thr?Arg?Arg?Arg?Tyr?Ser?Ser?Val?Gln?Glu?Pro?Gln?Ala?Lys
85 90 95 100GTG?CCT?AGC?AAA?CGA?ACA?CAG?AAA?CGC?CAC?AGA?GGA?TCC?CAA?GTT?GTC?ACC?TGC?CCA?CAT 360Val?Pro?Cys?Lys?Arg?Thr?Gln?Lys?Arg?His?Arg?Gly?Ser?Gln?Val?Val?Thr?Cys?Pro?His
105 110 115 120AAA?AAA?TCG?ACA?GCC?GCG?GTC?ATT?CTC?ACA?CCG?ACG?GAG?AAC?CAC?TTC?ACT?CTC?AAG?TGC 420Lys?Lys?Ser?Thr?Ala?Ala?Val?Ile?Leu?Thr?Pro?Thr?Glu?Asn?His?Phe?Thr?Leu?Lys?Cys
125 130 135 140CCT?AAA?ACA?GCG?CTC?ACA?GAG?CCT?CCC?ACT?CTT?GCG?TAC?TCA?CCC?AAC?AGG?CAA?ATC?TGC 480Pro?Lys?Thr?Ala?Leu?Thr?Glu?Pro?Pro?Thr?Leu?Ala?Tyr?Ser?Pro?Asn?Arg?Gln?Ile?Cys
145 150 155 160CCA?GCG?GGT?ACT?ACA?AGT?AGC?TGT?ACA?TCA?AAG?GCT?GTA?ACA?TTG?AGC?TCC?TTG?ATT?CCT 540Pro?Ala?Gly?Thr?Thr?Ser?Ser?Cys?Thr?Ser?Lys?Ala?Val?Thr?Leu?Ser?Ser?Leu?Ile?Pro
165 170 175 180GAA?GCA?GAA?GAT?AGC?TGG?TGG?ACG?GGG?GAT?TCT?GCT?AGT?CTG?GAC?ACG?GCA?GGC?ATC?AAA 600Glu?Ala?Glu?Asp?Ser?Trp?Trp?Thr?Gly?Asp?Ser?Ala?Ser?Leu?Asp?Thr?Ala?Gly?Ile?Lys
185 190 195 200CTC?ACA?GTT?CCA?ATC?GAG?AAG?TTC?CCC?GTG?ACA?ACG?CAG?ACG?TTT?GTG?GTC?GGT?TGC?ATC 660Leu?Thr?Val?Pro?Ile?Glu?Lys?Phe?Pro?Val?Thr?Thr?Gln?Thr?Phe?Val?Val?Gly?Cys?Ile
205 210 215 220AAG?GGA?GAC?GAC?GCA?CAG?AGC?TGT?ATG?GTC?ACG?GAG?ACA?GTA?CAA?GCC?AGA?GCC?TCA?TCG 720Lys?Gly?Asp?Asp?Ala?Gln?Ser?Cys?Met?Val?Thr?Glu?Thr?Val?Gln?Ala?Arg?Ala?Ser?Ser
225 230 235 240GTC?GTC?AAT?AAT?GTC?GCA?AGG?TGC?TCC?TAC?GGT?GCA?GAC?AGC?ACT?CTT?GGT?CCT?GTC?AAG 780Val?Val?Asn?Asn?Val?Ala?Arg?Cys?Ser?Tyr?Gly?Ala?Asp?Ser?Thr?Leu?Gly?Pro?Val?Lys
245 250 255 260GTG?TCT?GCG?GAA?GAA?CCC?ACT?ACA?ATG?ACC?CTC?GTG?TGC?GGG?AAA?GAT?GGA?GTC?AAA?GTT 840Val?Ser?Ala?Glu?Glu?Pro?Thr?Thr?Met?Thr?Leu?Val?Cys?Gly?Lys?Asp?Gly?Val?Lys?Val
265 270 275 280CCT?CAA?GAC?AAC?AAT?CAG?TAC?TGT?TCC?GGG?ACG?ACG?CTG?ACT?GGT?TGC?AAC?GAG?AAA?TCG 900Pro?Gln?Asp?Asn?Asn?Gln?Tyr?Cys?Ser?Gly?Thr?Thr?Leu?Thr?Gly?Cys?Asn?Glu?Lys?Ser
285 290 295 300TTC?AAA?GAT?ATT?TTG?CCA?AAA?TTA?ACT?GAG?AAC?CCG?TGG?CAG?GGT?AAC?GCT?TCG?AGT?GAT 960Phe?Lys?Asp?Ile?Leu?Pro?Lys?Leu?Thr?Glu?Asn?Pro?Trp?Gln?Gly?Asn?Ala?Ser?Ser?Asp
305 310 315 320AAG?GGT?GCC?ACG?CTA?ACG?ATC?AAG?AAG?GAA?GCA?TTT?CCA?GCC?GAG?TCA?AAA?AGC?GTC?ATT?1020Lys?Gly?Ala?Thr?Leu?Thr?Ile?Lys?Lys?Glu?Ala?Phe?Pro?Ala?Glu?Ser?Lys?Ser?Val?Ile
325 330 335 340ATT?GGA?TGC?ACA?GGG?GGA?TCG?CCT?GAG?AAG?CAT?CAC?TGT?ACC?GTG?AAA?CTG?GAG?TTT?GCC?1080Ile?Gly?Cys?Thr?Gly?Gly?Ser?Pro?Glu?Lys?His?His?Cys?Thr?Val?Lys?Leu?Glu?Phe?Ala
345 350 355 360GGG?GCT?GCA?GGG?TCA?GCA?AAA?TCG?GCT?GCG?GGA?TAA?1116Gly?Ala?Ala?Gly?Ser?Ala?Lys?Ser?Ala?Ala?Gly
365 370
Claims (4)
1. recombinant Toxoplasma fusion protein; Be that Infection of Toxoplasma Gondii GRA6 albumen n end is from the fusion of 313 amino acid whose 258 amino acid series connection formation of the 56th amino acid to the of 152 amino acid whose 110 amino acid of the 43rd amino acid to the and P30 albumen; 110 amino acid of GRA6 albumen n end are held at fusion N; 258 amino acid of P30 albumen are at the C of fusion end; Be connected Ser with serine by glycine (Gly) between the two) 2 amino acid connect; The N end of fusion has increased by 1 egg base acid (Met); 371,：Met Ala Ala Asp Ser Gly Gly Val Lys Gln Thr Pro Ser Glu Thr Gly Ser SerGly Gly Gln Gln Glu Ala Val Gly Thr Thr Glu Asp Tyr Val Asn Ser Ser AlaMet Gly Gly Gly Gln Gly Asp Ser Leu Ala Glu Asp Asp Thr Thr Ser Glu AlaAla Glu Gly Asp Val Asp Pro Phe Pro Val Leu Ala Asn Glu Gly Lys Ser GluAla Arg Gly Pro Ser Leu Glu Glu Arg Ile Glu Glu Gln Gly Thr Arg Arg ArgTyr Ser Ser Val Gln Glu Pro Gln Ala Lys Val Pro Cys Lys Arg Thr Gln LysArg His Arg Gly Ser Gln Val Val Thr Cys Pro His Lys Lys Ser Thr Ala AlaVal Ile Leu Thr Pro Thr Glu Asn His Phe Thr Leu Lys Cys Pro Lys Thr AlaLeu Thr Glu Pro Pro Thr Leu Ala Tyr Ser Pro Asn Arg Gln Ile Cys Pro AlaGly Thr Thr Ser Ser Cys Thr Ser Lys Ala Val Thr Leu Ser Ser Leu Ile ProGlu Ala Glu Asp Ser Trp Trp Thr Gly Asp Ser Ala Ser Leu Asp Thr Ala GlyIle Lys Leu Thr Val Pro Ile Glu Lys Phe Pro Val Thr Thr Gln Thr Phe ValVal Gly Cys Ile Lys Gly Asp Asp Ala Gln Ser Cys Met Val Thr Glu Thr ValGln Ala Arg Ala Ser Ser Val Val Asn Asn Val Ala Arg Cys Ser Tyr Gly AlaAsp Ser Thr Leu Gly Pro Val Lys Val Ser Ala Glu Glu Pro Thr Thr Met ThrLeu Val Cys Gly Lys Asp Gly Val Lys Val Pro Gln Asp Asn Asn Gln Tyr CysSer Gly Thr Thr Leu Thr Gly Cys Asn Glu Lys Ser Phe Lys Asp Ile Leu ProLys Leu Thr Glu Asn Pro Trp Gln Gly Asn Ala Ser Ser Asp Lys Gly Ala ThrLeu Thr Ile Lys Lys Glu Ala Phe Pro Ala Glu Ser Lys Ser Val Ile Ile GlyCys Thr Gly Gly Ser Pro Glu Lys His His Cys Thr Val Lys Leu Glu Phe AlaGly Ala Ala Gly Ser Ala Lys Ser Ala Ala Gly
2. the preparation method of the described recombinant toxoplasma fusion rotein of claim 1, this albumen is to utilize the genetic engineering technique preparation, concrete grammar is as follows: the gene clone of toxoplasma gondii GRA6 albumen and P30 proteantigen epi-position:
Select design PCR primer in the both sides of the dna sequence dna of shape worm GRA6 proteantigen epi-position, the upstream primer of design is GRA6P1 (547-565bp): 5 '-GCGAGTCA
CCATGGCAGCAGACAGCGGTGGTG-3 '; Downstream primer is GRA6P2 (856-876bp): 5 '-CGC
GGATCCTCTGTGGCGTTTCTGTGTTCG-3 ' has increased Nco I restriction enzyme site (following setting-out part) on upstream primer, and has increased by 8 protection bases at 5 ' weak point, is beneficial to the cutting of Nco I enzyme.On downstream primer, increase BamHI restriction enzyme site (following setting-out part);
Select design PCR primer in the both sides of the dna sequence dna of shape worm P30 proteantigen epi-position, the upstream primer of design is P30P3 (166-184bp): 5 '-CTG
GGATCCCAAGTTGTCACCTGCCCA-3 '; Downstream primer is P30P4 (922-939bp): 5 '-GTC
GAATTCTTATCCCGCAGCCGATTTTGC-3 ', on upstream primer, increased BamHI restriction enzyme site (following setting-out part), and short increased by 3 protection bases 5 ', and be beneficial to the cutting of BamHI enzyme, on downstream primer, increase EcoRI restriction enzyme site (following setting-out part) and give terminator codon (italic);
Bow-shaped worm dna with purification is a template, gene fragment with primer GRA6P1 and GRA6P2 pcr amplification toxoplasma gondii GRA6 proteantigen epi-position, gene fragment with primer P30P3 and P30P4 pcr amplification toxoplasma gondii P30 proteantigen epi-position, amplification condition is: 94 ℃ 30 seconds, 65 ℃ 30 seconds, 72 ℃ 60 seconds, 35 circulations; Last 72 ℃ were extended 7 minutes.Electrophoresis reclaims, the gene fragment of purifying amplification, is dissolved in the deionized water, put-20 ℃ frozen standby; Express toxoplasma gondii GRA6 and P30 fusion rotein construction of recombinant plasmid:
Extract plasmid pET28a (+) (U.S. Novagen company product), with Nco I and EcoR I double digestion, reclaim the big fragment of plasmid that enzyme is cut behind the electrophoresis, be dissolved in the deionized water, with NcoI and BamHI double digestion toxoplasma gondii GRA6 gene fragment, its 5 ' formation Nco I sticky end, 3 ' end is dissolved in the deionized water, with the P30 protein gene fragment of EcoR I and BamH I double digestion purifying after forming the recovery of BamH I sticky end electrophoresis, electrophoresis is dissolved in the deionized water after reclaiming;
Above-mentioned three kinds of enzymes of volumetric molar concentration such as get and cut the back dna fragmentation, in same centrifuge tube, connect with the T4 dna ligase, toxoplasma gondii GRA6 gene fragment is connected with P30 protein gene fragment be inserted between carrier pET28a (+) interior the Nco I and EcoR I site, both translate the framework unanimity, express a fusion rotein; The screening of recombinant plasmid and evaluation:
With recombinant plasmid transformed e. coli bl21 (DE3), coating contains kantlex (60 μ g/ml) LB flat board, puts 37 ℃ and spends the night.Next day, picking transformed a bacterium colony and a contrast bacterium (plasmid pET28a transformed bacteria) at random, extract plasmid respectively, it is right at first to form primer with primer GRA6P1 and primer P30P4, with the plasmid that extracts is that template is carried out the PCR evaluation, the plasmid that contains toxoplasma gondii GRA6 gene fragment and P30 protein gene fragment tandem gene, should amplify a 1132bp gene fragment, the plasmid that extraction contains toxoplasma gondii GRA6 protein gene fragment and P30 protein gene fragment tandem gene carries out dna sequence analysis, sequential analysis confirms that recombinant plasmid contains placed in-line toxoplasma gondii GRA6 gene fragment and P30 protein gene fragment, and sequence is entirely true: ATG GCA GCA GAC AGC GGT GGT GTT AAG CAG ACC CCT TCG GAA ACC GGT TCG AGCGGT GGA CAG CAA GAA GCA GTG GGG ACC ACT GAA GAC TAT GTC AAC TCT TCG GCGATG GGC GGT GGC CAA GGC GAC TCG TTA GCT GAA GAT GAT ACA ACC TCC GAA GCGGCG GAG GGC GAC GTT GAC CCT TTT CCC GTG CTG GCG AAT GAG GGG AAG TCG GAGGCG CGT GGC CCG TCG CTC GAG GAA AGA ATC GAA GAA CAG GGC ACA AGA CGA CGTTAC TCC TCT GTT CAA GAA CCA CAA GCG AAG GTG CCT AGC AAA CGA ACA CAG AAACGC CAC AGA
GGA TCCCAA GTT GTC ACC TGC CCA CAT AAA AAA TCG ACA GCC GCGGTC ATT CTC ACA CCG ACG GAG AAC CAC TTC ACT CTC AAG TGC CCT AAA ACA GCGCTC ACA GAG CCT CCC ACT CTT GCG TAC TCA CCC AAC AGG CAA ATC TGC CCA GCGGGT ACT ACA AGT AGC TGT ACA TCA AAG GCT GTA ACA TTG AGC TCC TTG ATT CCTGAA GCA GAA GAT AGC TGG TGG ACG GGG GAT TCT GCT AGT CTG GAC ACG GCA GGCATC AAA CTC ACA GTT CCA ATC GAG AAG TTC CCC GTG ACA ACG CAG ACG TTT GTGGTC GGT TGC ATC AAG GGA GAC GAC GCA CAG AGC TGT ATG GTC ACG GAG ACA GTACAA GCC AGA GCC TCA TCG GTC GTC AAT AAT GTC GCA AGG TGC TCC TAC GGT GCAGAC AGC ACT CTT GGT CCT GTC AAG GTG TCT GCG GAA GAA CCC ACT ACA ATG ACCCTC GTG TGC GGG AAA GAT GGA GTC AAA GTT CCT CAA GAC AAC AAT CAG TAC TGTTCC GGG ACG ACG CTG ACT GGT TGC AAC GAG AAA TCG TTC AAA GAT ATT TTG CCAAAA TTA ACT GAG AAC CCG TGG CAG GGT AAC GCT TCG AGT GAT AAG GGT GCC ACGCTA ACG ATC AAG AAG GAA GCA TTT CCA GCC GAG TCA AAA AGC GTC ATT ATT GGATGC ACA GGG GGA TCG CCT GAG AAG CAT CAC TGT ACC GTG AAA CTG GAG TTT GCCGGG GCT GCA GGG TCA GCA AAA TCG GCT GCG GGA TAAGRA6P30； Be connected Ser with serine by glycine (Gly) between the two) 2 amino acid connect; Wherein Infection of Toxoplasma Gondii GRA6 albumen is at the N of fusion end, and P30 albumen is at the C of fusion end; The Screening and Identification of expressed fusion protein engineering bacteria:
Transformant is seeded to contains 3ml LB substratum (containing kanamycin 60 μ g/ml) in vitro, 37 ℃ of shaking culture 3h, add IPTG to final concentration 0.5mmol/L, continue shaking culture and induce 6h, centrifugal collection thalline carries out SDS-PAGE and detects, recon is expressed relative molecular weight and is about 39000 fusion rotein, and expression amount is about 28%, and contrast bacterium BL21 (DE3) does not have this protein band; The purifying of expressed fusion protein:
1) ultrasonic degradation of expressed fusion protein engineering bacteria
Centrifugal (8000rpm, 10min, 4 ℃) receives bacterium with the engineering bacteria of abduction delivering fusion rotein, thalline is resuspended in the lysate (50mmol/L Tris-HCl pH8.14,10mmol/L EDTA, 10mmol/L DTT, 5% glycerine) of original fluid 1/10 volume, ice-bath ultrasonic is broken bacterium 10min, centrifugal (12000rpm, 20min, 4 ℃) collecting precipitation inclusion body;
2) cracking of inclusion body
Inclusion body suspends with 0.5%SKL (with 50mmol/L Tris-HCl pH8.14,0.5mmol/L EDTA, the preparation of 0.25mmol/L DTT balance liquid) solution, room temperature cracking inclusion body 1h, centrifugal (12000rpm, 20min, 4 ℃), collect supernatant, in the dialysis tubing of packing into 1000ml balance liquid (50mmol/L Tris-HClpH8.14,0.5mmol/L EDTA, 0.25mmol/L DTT) is dialysed.4 ℃ of dialysed overnight are changed dialyzate next day 2 times, each 1000ml, and centrifugal (8000rpm, 20min, 4 ℃) collects DEAE-SepharoseFF anion column purifying on the supernatant;
3) DEAE-Sepharose FF anion column purifying
DEAE-Sepharose FF anion column is connected to the normal pressure chromatographic system, earlier with balance liquid (50mmol/LTris-HCl pH8.14,0.5mmol/L EDTA, 0.25mmol/L DTT) flushing balance, to go up the cracking supernatant of step acquisition then and directly go up sample, last sample flow velocity is 1.5ml/min, the peak is passed in collection, wash with balance liquid behind the last sample, then successively with containing 50,100,200,300, the balance liquid eluted protein of 1000mmol/L NaCl, collect each elution peak albumen, pass this peak, peak and each elution peak albumen with the 12%SDS-PAGE detection, collect 300mmol/L NaCl elution peak and be GRA6 and P30 fusion rotein; The fusion rotein of purifying is used as the Detection of antigen toxoplasma antibody:
The fusion rotein of purifying is wrapped by elisa plate with carbonate (pH9.6) the dilution back of 50mmol/L, the indirect enzyme-linked immunosorbent method detects known resisting toxoplasmosis IgM (or IgG) positive serum and normal human serum, the result shows, fusion rotein can react with resisting toxoplasmosis IgM (or IgG) positive serum positive serum,, do not illustrate that this fusion rotein has antigenicity and specificity preferably with the normal human serum reaction;
Same with this fusion rotein of horseradish peroxidase (HRP) mark, detect resisting toxoplasmosis IgM or IgG antibody with pouncing on the method that obtains, higher susceptibility and specificity are arranged, this fusion rotein is as antigen, detect resisting toxoplasmosis IgM or IgG antibody with gold mark method, higher susceptibility and specificity are also arranged.
3. claim 1 or 2 described recombinant toxoplasma fusion rotein and gene orders thereof utilize bacterium, yeast cell, insect cell and mammalian cell to carry out recombinant expressed, preparation.
4. claim 1 or 2 described recombinant toxoplasma fusion roteins reach in anti-human cytomegalic inclusion disease virus monoclonal antibody of preparation and the application in resist at detection human cytomegalic inclusion disease virus antibody or antigen more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031134297A CN1194991C (en) | 2003-05-09 | 2003-05-09 | Recombinant Toxoplasma fusion protein antigen and preparation process and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031134297A CN1194991C (en) | 2003-05-09 | 2003-05-09 | Recombinant Toxoplasma fusion protein antigen and preparation process and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1450087A true CN1450087A (en) | 2003-10-22 |
| CN1194991C CN1194991C (en) | 2005-03-30 |
Family
ID=28684067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031134297A Expired - Fee Related CN1194991C (en) | 2003-05-09 | 2003-05-09 | Recombinant Toxoplasma fusion protein antigen and preparation process and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1194991C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006094665A1 (en) * | 2005-03-08 | 2006-09-14 | Kenton Srl | Chimeric recombinant antigens of toxoplasma gondii |
| CN100398150C (en) * | 2005-09-16 | 2008-07-02 | 中国农业科学院兰州兽医研究所 | Toxoplasma metabolic secretion antigen vaccine and its prepn process |
| CN1861633B (en) * | 2005-05-10 | 2011-09-14 | 陈晓光 | Toxophasma gondii detecting kit based on recombined antigen |
| CN101565465B (en) * | 2008-05-14 | 2011-12-21 | 复旦大学 | Surface antigen 1 of Toxoplasma gondii human antibody Fab fragment and encoded gene thereof |
| CN102492696A (en) * | 2011-12-13 | 2012-06-13 | 北京英诺特生物技术有限公司 | Recombinant toxoplasma protein and application thereof |
| CN102827292A (en) * | 2012-09-19 | 2012-12-19 | 南京医科大学第二附属医院 | Fusion protein TgMEP as well as preparation method and application thereof |
| CN105759030A (en) * | 2016-03-15 | 2016-07-13 | 中国农业大学 | Colloidal gold test strip for testing toxoplasma gondii antibodies |
| CN111116726A (en) * | 2020-01-14 | 2020-05-08 | 中国农业科学院北京畜牧兽医研究所 | Recombinant protein for detecting toxoplasma gondii and coding gene thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100554965C (en) * | 2005-08-05 | 2009-10-28 | 珠海经济特区海泰生物制药有限公司 | Toxoplasmosis IgM antigen testing reagent and application |
-
2003
- 2003-05-09 CN CNB031134297A patent/CN1194991C/en not_active Expired - Fee Related
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006094665A1 (en) * | 2005-03-08 | 2006-09-14 | Kenton Srl | Chimeric recombinant antigens of toxoplasma gondii |
| EA013349B1 (en) * | 2005-03-08 | 2010-04-30 | Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. | Chimeric recombinant antigens of toxoplasma gondii |
| US7790187B2 (en) | 2005-03-08 | 2010-09-07 | Kenton S.R.L. | Chimeric recombinant antigens of Toxoplasma gondii |
| US7867503B2 (en) | 2005-03-08 | 2011-01-11 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Chimeric recombinant antigens of Toxoplasma gondii |
| CN1861633B (en) * | 2005-05-10 | 2011-09-14 | 陈晓光 | Toxophasma gondii detecting kit based on recombined antigen |
| CN100398150C (en) * | 2005-09-16 | 2008-07-02 | 中国农业科学院兰州兽医研究所 | Toxoplasma metabolic secretion antigen vaccine and its prepn process |
| CN101565465B (en) * | 2008-05-14 | 2011-12-21 | 复旦大学 | Surface antigen 1 of Toxoplasma gondii human antibody Fab fragment and encoded gene thereof |
| CN102492696A (en) * | 2011-12-13 | 2012-06-13 | 北京英诺特生物技术有限公司 | Recombinant toxoplasma protein and application thereof |
| CN102492696B (en) * | 2011-12-13 | 2014-01-29 | 北京英诺特生物技术有限公司 | Recombinant toxoplasma protein and application thereof |
| CN102827292A (en) * | 2012-09-19 | 2012-12-19 | 南京医科大学第二附属医院 | Fusion protein TgMEP as well as preparation method and application thereof |
| CN105759030A (en) * | 2016-03-15 | 2016-07-13 | 中国农业大学 | Colloidal gold test strip for testing toxoplasma gondii antibodies |
| CN105759030B (en) * | 2016-03-15 | 2018-01-02 | 中国农业大学 | A kind of colloidal gold strip for detecting toxoplasma antibody |
| CN111116726A (en) * | 2020-01-14 | 2020-05-08 | 中国农业科学院北京畜牧兽医研究所 | Recombinant protein for detecting toxoplasma gondii and coding gene thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1194991C (en) | 2005-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105079781B (en) | Composition for treating chylous diarrhea and method | |
| JPH02501192A (en) | DNA sequences, recombinant DNA molecules and methods for producing soluble T4 protein | |
| KR20190110605A (en) | Swine Coronavirus Vaccine | |
| AU690900B2 (en) | Allergenic protein and peptides from house dust mite and uses therefor | |
| CN112876542B (en) | Novel epitope peptide of coronavirus T cell and application thereof | |
| CN1450087A (en) | Recombinant Toxoplasma fusion protein antigen and preparation process and use thereof | |
| CN113512096A (en) | Weever rhabdovirus recombinant G2 protein and application thereof | |
| CN111840530A (en) | Preparation method of Eimeria tenella recombinant polypeptide vaccine VNQS and application method thereof in chicken coccidiosis resistance | |
| CN102307894B (en) | A variant of mite allergen and uses thereof | |
| CN110272910A (en) | A kind of outer membrane vesicles and its application of the recombinant vector including JEV antigen gene, recombinant bacterial strain and submission JEV antigen | |
| CN109207502A (en) | Porcine mycoplasmal pneumonia and porcine circovirus 2 type recombinant protein and prepare bigeminy vaccine | |
| CN110201188B (en) | Kochia pollen allergen extract, extract thereof and preparation method thereof | |
| Hashizume et al. | Development and evaluation of transgenic rice seeds accumulating a type II-collagen tolerogenic peptide | |
| CN106226520A (en) | Antigen of mycobacterium tuberculosis albumen Rv0865 and the application of B cell epitope peptide thereof | |
| CN107551264A (en) | L3 and/or L5 sources are as parasitic disease vaccine or the purposes of diagnosis | |
| CN116059337B (en) | Novel adjuvant recombinant herpes zoster vaccine and preparation and application thereof | |
| JP3649460B2 (en) | Japanese cedar pollen allergen Cry j II epitope | |
| CN110257405A (en) | Mycoplasma bovis alcohol dehydrogenase gene and its coding albumen and application | |
| WO1999016467A1 (en) | Non-anaphylactic forms of allergens and their use | |
| CN113736825A (en) | Recombinant drosophila cell line for expressing swine atypical pestivirus fusion protein and preparation method and application thereof | |
| CN115166235A (en) | African swine fever virus double-antigen sandwich antibody detection kit and preparation method thereof | |
| AU763299B2 (en) | Histamine and serotonin binding molecules | |
| CN101899419B (en) | Insect baculovirus expression system and method for expressing E2 protein using same | |
| CN113640524B (en) | Composite antigen for detecting haemonchus contortus infection and application thereof | |
| CN113248627B (en) | Antigen for enhancing porcine epidemic diarrhea immunity and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |